파킨슨 병 이외의 적응증을 가진 환자의 Pramipexole 혹은 Ropinirole 사용과 관련된 충동 조절 장애: 주제 범위 문헌 고찰
Impulse Control Disorders associated with Pramipexole/Ropinirole Use in Non-Parkinson’s Disease: A Scoping Review
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Dopamine receptor agonists (DRAs) have been associated with impulse control disorders (ICDs) in Parkinson’s disease (PD) in preliminary studies. Whether the association holds true when DRAs are used to treat non-PD, such as restless legs syndrome, prolactinoma, and several mood disorders is uncertain. Objective: The present study aimed to understand the research gaps related to the risk of ICDs associated with pramipexole or ropinirole (PRX/ROP) use as a treatment for specific underlying diseases, excluding Parkinson’s disorders. Methods: We conducted a scoping review, systematically searching databases to identify literature on the types, prevalence, and factors associated with ICD in non-PD patients receiving PRX/ROP. All relevant information that helped understand the epidemiology of ICDs among non-PD patients taking PRX/ROP were extracted and analyzed. We also evaluated the potential associations between PRX/ROP and ICDs, utilizing the Naranjo scale or statistical analysis, depending on the type of literature. Results: We included 24 articles (19 case reports or case series and 5 populationbased studies) in this scoping review. Evaluating the 19 case reports or case series using Naranjo scores led to the discovery of a possible link between PRX/ROP exposure and ICDs. However, important information to assess causality is frequently missing. Moreover, the population-based studies lack diversity in the study populations and enough study samples to draw conclusive results. Conclusion: Our scoping review suggests that the currently available literature requires more details in future case reports and for well-powered studies in various disease conditions where PRX/ROP is frequently used.
Abstract
Background: Dopamine receptor agonists (DRAs) have been associated with impulse control disorders (ICDs) in Parkinson’s disease (PD) in preliminary studies. Whether the association holds true when DRAs are used to treat non-PD, such as restless legs syndrome, prolactinoma, and several mood disorders is uncertain. Objective: The present study aimed to understand the research gaps related to the risk of ICDs associated with pramipexole or ropinirole (PRX/ROP) use as a treatment for specific underlying diseases, excluding Parkinson’s disorders. Methods: We conducted a scoping review, systematically searching databases to identify literature on the types, prevalence, and factors associated with ICD in non-PD patients receiving PRX/ROP. All relevant information that helped understand the epidemiology of ICDs among non-PD patients taking PRX/ROP were extracted and analyzed. We also evaluated the potential associations between PRX/ROP and ICDs, utilizing the Naranjo scale or statistical analysis, depending on the type of literature. Results: We included 24 articles (19 case reports or case series and 5 populationbased studies) in this scoping review. Evaluating the 19 case reports or case series using Naranjo scores led to the discovery of a possible link between PRX/ROP exposure and ICDs. However, important information to assess causality is frequently missing. Moreover, the population-based studies lack diversity in the study populations and enough study samples to draw conclusive results. Conclusion: Our scoping review suggests that the currently available literature requires more details in future case reports and for well-powered studies in various disease conditions where PRX/ROP is frequently used.
참고문헌 (32)
- 김종오, "충동조절 장애범죄의 심리적 접근", 한국범죄심리연구, 11(3), pp.53~76 (2015), 한국범죄심리학회
- Leroi I, "Carer burden in apathy and impulse control disorders in Parkinson’s disease", Int J Geriatr Psychiatry, 27(2), pp.160~166 (2012)
- Callesen MB, "A systematic review of impulse control disorders in Parkinson’s disease", J Parkinsons Dis, 3(2), pp.105~138 (2013)
- Molde H, "Impulse-control disorders in Parkinson’s disease : a metaanalysis and review of case-control studies", Front Neurol, 9, pp.330~ (2018)
- Gatto EM, "Impulse control disorders in Parkinson’s disease. A brief and comprehensive review", Front Neurol, 10, pp.351~ (2019)
- Weintraub D, "Association of dopamine agonist use with impulse control disorders in Parkinson disease", Arch Neurol, 63(7), pp.969~973 (2006)
- Seeman P, "Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors", Synapse, 69(4), pp.183~189 (2015)
- Rizos A, "A european multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short-and long-acting dopamine agonists", Eur J Neurol, 23(8), pp.1255~1261 (2016)
- Grall-Bronnec M, "Dopamine agonists and impulse control disorders : A complex association", Drug Saf, 41(1), pp.19~75 (2018)
- Schreiber L, "Impulse control disorders : updated review of clinical characteristics and pharmacological management", Front psychiatry, 2, pp.1~ (2011)
- Ohayon MM, "Epidemiology of restless legs syndrome : A synthesis of the literature", Sleep Med Rev, 16(4), pp.283~295 (2012)
- Ciccarelli A, "The epidemiology of prolactinomas", Pituitary, 8(1), pp.3~6 (2005)
- Sucharew H, "Methods for research evidence synthesis : The scoping review approach", J Hosp Med, 14(7), pp.416~418 (2019)
- Arksey H, "Scoping studies : towards a methodological framework", Int J Soc Res Methodol, 8(1), pp.19~32 (2005)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30(2), pp.239~245 (1981)
- Voon V, "Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome", BMC Neurol, 11(1), pp.117~ (2011)
- Bayard S, "Decision-making, rewardseeking behaviors and dopamine agonist therapy in restless legs syndrome", Sleep, 36(10), pp.1501~1507 (2013)
- Heim B, "Augmentation and impulsive behaviors in restless legs syndrome : Coexistence or association", Neurology, 87(1), pp.36~40 (2016)
- Montagna P, "Randomized trial of pramipexole for patients with restless legs syndrome(RLS)and RLS-related impairment of mood", Sleep Med, 12(1), pp.34~40 (2011)
- Lipford MC, "Long-term use of pramipexole in the management of restless legs syndrome", Sleep Med, 13(10), pp.1280~1285 (2012)
- Tricco AC, "PRISMA extension for scoping reviews(PRISMA-ScR) : Checklist and explanation", Ann Intern Med, 169(7), pp.467~473 (2018)
- Leeman RF, "Impulse control disorders in Parkinson’s disease: clinical characteristics and implications", Neuropsychiatry (London), 1(2), pp.133~147 (2011)
- Kolla BP, "Impact of dopamine agonists on compulsive behaviors : A case series of pramipexole-induced pathological gambling", Psychosomatics, 51(3), pp.271~273 (2010)
- Driver-Dunckley ED, "Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome", Clin Neuropharmacol, 30(5), pp.249~255 (2007)
- Cornelinus J, "Impulse control disorders with the use of dopaminergic agents in restless legs syndrome : a case-control study", Sleep, 33(1), pp.81~87 (2010)
- Mishima T, "Impulse control disorders and punding in Perry syndrome", Parkinsonism Relat Disord, 21(11), pp.1381~1382 (2015)
- Tajima-Pozo K, "Paraphilia as adverse drug reaction to dopamine agonist(Pramipexole)", Acta Neuropsychiatr, 23(2), pp.89~ (2011)
- Strejilevich SA, "Pathological gambling in a bipolar patient treated with pramipexole", J Neuropsychiatry Clin Neurosci, 23(1), pp.E2~E3 (2011)
- Maruo J, "Abnormal behaviours during pramipexole treatment for Cotard’s syndrome : a case report", Psychogeriatrics, 16(4), pp.283~286 (2016)
- Larson ER, "Neuropsychological findings in a case of punding before and after cessation of pramipexole", Clin Neuropsychol, 29(1), pp.166~178 (2015)
- Corvol JC, "Longitudinal analysis of impulse control disorders in Parkinson disease", Neurology, 91(3), pp.e189~e201 (2018)
- Lizarraga KJ, "Hallucinations, delusions and impulse control disorders in Parkinson disease", Clin Geriatr Med, 36(1), pp.105~118 (2019)